MicroRNAs in CD4+ T cell subsets are markers of disease risk and T cell dysfunction in individuals at risk for type 1 diabetes

Journal of Autoimmunity

Volumn 68, Issue , 2016, Pages 52-61

  Zhang, Yuxia ^a,b,c   Feng, Zhi Ping ^a,b   Naselli, Gaetano ^a   Bell, Fiona ^a   Wettenhall, James ^a,e   Auyeung, Priscilla ^a   Ellis, Justine A ^b,d   Ponsonby, Anne Louise ^b,d   Speed, Terence P ^a,b   Chong, Mark M W ^a,b,f   Harrison, Leonard C ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

EZH2; FOXP3; MiR 26a; MiRNA; NTreg; TIGIT; Type 1 diabetes

Indexed keywords

MICRORNA; MICRORNA 15A; MICRORNA 26A; MICRORNA 31; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR FOXP3; BIOLOGICAL MARKER;

ARTICLE; CD4+ T LYMPHOCYTE; CELL FRACTIONATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEMORY T LYMPHOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CLUSTER ANALYSIS; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOCYTE ACTIVATION; MICRORNAS; T-LYMPHOCYTE SUBSETS;

EID: 84960108003     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.12.006     Document Type: Article

References (48)

1. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
2. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27:20-21.
3. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
4. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415.
5. Garg G., Tyler J.R., Yang J.H., Cutler A.J., Downes K., Pekalski M., et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J. Immunol. 2012, 188:4644-4653.
6. Hulme M.A., Wasserfall C.H., Atkinson M.A., Brusko T.M. Central role for interleukin-2 in type 1 diabetes. Diabetes 2012, 61:14-22.
7. Zhou X., Bailey-Bucktrout S.L., Jeker L.T., Penaranda C., Martinez-Llordella M., Ashby M., et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 2009, 10:1000-1007.
8. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60:2903-2913.
9. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
10. Lu L.F., Boldin M.P., Chaudhry A., Lin L.L., Taganov K.D., Hanada T., et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010, 142:914-929.
11. Lu L.F., Thai T.H., Calado D.P., Chaudhry A., Kubo M., Tanaka K., et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009, 30:80-91.
12. Guay C., Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat. Rev. Endocrinol. 2013, 9:513-521.
13. Nielsen L.B., Wang C., Sorensen K., Bang-Berthelsen C.H., Hansen L., Andersen M.L., et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp. diabetes Res. 2012, 2012:896362.
14. Salas-Perez F., Codner E., Valencia E., Pizarro C., Carrasco E., Perez-Bravo F. MicroRNAs miR-21a and miR-93 are down regulated in peripheral blood mononuclear cells (PBMCs) from patients with type 1 diabetes. Immunobiology 2013, 218:733-737.
15. Sebastiani G., Grieco F.A., Spagnuolo I., Galleri L., Cataldo D., Dotta F. Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes/metab. Res. Rev. 2011, 27:862-866.
16. Hezova R., Slaby O., Faltejskova P., Mikulkova Z., Buresova I., Raja K.R., et al. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 2010, 260:70-74.
17. Ellis J.A., Ponsonby A.L., Pezic A., Chavez R.A., Allen R.C., Akikusa J.D., et al. CLARITY - ChiLdhood arthritis risk factor identification sTudY. Pediatr. rheumatol. online J. 2012, 10:37.
18. Harrison L.C. Risk assessment, prediction and prevention of type 1 diabetes. Pediatr. Diabetes 2001, 2:71-82.
19. Torn C., Mueller P.W., Schlosser M., Bonifacio E., Bingley P.J., Participating L. Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008, 51:846-852.
20. Williams A.J., Bingley P.J., Chance R.E., Gale E.A. Insulin autoantibodies: more specific than proinsulin autoantibodies for prediction of type 1 diabetes. J. Autoimmun. 1999, 13:357-363.
21. Hafner M., Landgraf P., Ludwig J., Rice A., Ojo T., Lin C., et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing. Methods 2008, 44:3-12.
22. Chong M.M., Zhang G., Cheloufi S., Neubert T.A., Hannon G.J., Littman D.R. Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev. 2010, 24:1951-1960.
23. Kirigin F.F., Lindstedt K., Sellars M., Ciofani M., Low S.L., Jones L., et al. Dynamic microRNA gene transcription and processing during T cell development. J. Immunol. 2012, 188:3257-3267.
24. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39:D152-D157.
25. Law C.W., Chen Y., Shi W., Smyth G.K. Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014, 15:R29.
26. Herold M.J., van den Brandt J., Seibler J., Reichardt H.M. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18507-18512.
27. Cao P., Deng Z., Wan M., Huang W., Cramer S.D., Xu J., et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol. cancer 2010, 9:108.
28. Farh K.K., Marson A., Zhu J., Kleinewietfeld M., Housley W.J., Beik S., et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2015, 518:337-343.
29. Zhang Y., Kinkel S., Maksimovic J., Bandala-Sanchez E., Tanzer M.C., Naselli G., et al. The polycomb repressive complex 2 governs life and death of peripheral T cells. Blood 2014, 124:737-749.
30. Tumes D.J., Onodera A., Suzuki A., Shinoda K., Endo Y., Iwamura C., et al. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. Immunity 2013, 39:819-832.
31. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13944-13949.
32. Pezzolesi M.G., Satake E., McDonnell K.P., Major M., Smiles A.M., Krolewski A.S. Circulating TGF-beta1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes. Diabetes 2015 Sep, 64(9):3285-3293. (Epub 2015 Apr 30). 10.2337/db15-0116.
33. Rouas R., Fayyad-Kazan H., El Zein N., Lewalle P., Rothe F., Simion A., et al. Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur. J. Immunol. 2009, 39:1608-1618.
34. Zhu S., Pan W., Song X., Liu Y., Shao X., Tang Y., et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat. Med. 2012, 18:1077-1086.
35. Lu J., He M.L., Wang L., Chen Y., Liu X., Dong Q., et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011, 71:225-233.
36. Arvey A., van der Veeken J., Samstein R.M., Feng Y., Stamatoyannopoulos J.A., Rudensky A.Y. Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. Nat. Immunol. 2014 Jun, 15(6):580-587. (Epub 2014 Apr 13). 10.1038/ni.2868.
37. DuPage M., Chopra G., Quiros J., Rosenthal W.L., Morar M.M., Holohan D., et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 2015, 42:227-238.
38. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
39. Zhang Y., Maksimovic J., Naselli G., Qian J., Chopin M., Blewitt M.E., et al. Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells. Blood 2013, 122:2823-2836.
40. Noren Hooten N., Abdelmohsen K., Gorospe M., Ejiogu N., Zonderman A.B., Evans M.K. microRNA expression patterns reveal differential expression of target genes with age. PloS one 2010, 5:e10724.
41. Petrich de Marquesini L.G., Fu J., Connor K.J., Bishop A.J., McLintock N.E., Pope C., et al. IFN-gamma and IL-10 islet-antigen-specific T cell responses in autoantibody-negative first-degree relatives of patients with type 1 diabetes. Diabetologia 2010, 53:1451-1460.
42. Johnston R.J., Comps-Agrar L., Hackney J., Yu X., Huseni M., Yang Y., et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer cell 2014, 26:923-937.
43. Kurtulus S., Sakuishi K., Ngiow S.F., Joller N., Tan D.J., Teng M.W., et al. TIGIT predominantly regulates the immune response via regulatory T cells. J. Clin. Investig. 2015, 125:4053-4062.
44. Ma H., Zhang S., Shi D., Mao Y., Cui J. MicroRNA-26a promotes regulatory t cells and suppresses autoimmune diabetes in mice. Inflammation 2015, Jul 26. (Epub ahead of print).
45. De Aizpurua H.J., French M.B., Chosich N., Harrison L.C. Natural history of humoral immunity to glutamic acid decarboxylase in non-obese diabetic (NOD) mice. J. Autoimmun. 1994, 7:643-653.
46. Fu X., Dong B., Tian Y., Lefebvre P., Meng Z., Wang X., et al. MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J. Clin. Investig. 2015, 125:2497-2509.
47. Bjork E., Kampe O., Karlsson F.A., Pipeleers D.G., Andersson A., Hellerstrom C., et al. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J. Clin. Endocrinol. metab. 1992, 75:1574-1576.
48. Swaminathan S., Suzuki K., Seddiki N., Kaplan W., Cowley M.J., Hood C.L., et al. Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J. Immunol. 2012, 188:6238-6246.